Evidence map›Paper›PMID 38502215›Full record

ReviewEuropean journal of nuclear medicine and molecular imaging2024

Near-infrared II theranostic agents for the diagnosis and treatment of Alzheimer's disease.

Can Zhou, Fantian Zeng, Haijun Yang, Zeying Liang, Guanyu Xu, Xiao Li, Xingdang Liu, Jian Yang

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Can Zhou411 Hospital, School of Medicine, Shanghai University, Shanghai, 200444, China.
Fantian ZengState Key Laboratory of Infectious Disease Vaccine Development, Xiang An Biomedicine Laboratory & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen, 361102, China.
Haijun Yang411 Hospital, School of Medicine, Shanghai University, Shanghai, 200444, China.
Zeying Liang411 Hospital, School of Medicine, Shanghai University, Shanghai, 200444, China.
Guanyu Xu411 Hospital, School of Medicine, Shanghai University, Shanghai, 200444, China.
Xiao LiShanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai, 201800, China. lixiao@sinap.ac.cn.
Xingdang LiuDepartment of Nuclear Medicine, Pudong Hospital, Fudan University, Shanghai, 201399, China. xingdliu@fudan.edu.cn.
Jian Yang411 Hospital, School of Medicine, Shanghai University, Shanghai, 200444, China. yj_scu@163.com.ORCID 0000-0002-5145-936X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNear-infrared II theranostic agents have gained great momentum in the research field of AD owing to the appealing advantages. Recently, an array of activatable NIR-II fluorescence probes has been developed to specifically monitor pathological targets of AD. Furthermore, various NIR-II-mediated nanomaterials with desirable photothermal and photodynamic properties have demonstrated favorable outcomes in the management of AD.

methodsWe summerized amounts of references and focused on small-molecule probes, nanomaterials, photothermal therapy, and photodynamic therapy based on NIR-II fluorescent imaging for the diagnosis and treatment in AD. In addition, design strategies for NIR-II-triggered theranostics targeting AD are presented, and some prospects are also addressed.

resultsNIR-II theranostic agents including small molecular probes and nanoparticles have received the increasing attention for biomedical applications. Meanwhile, most of the theranostic agents exhibited the promising results in animal studies. To our surprise, the multifunctional nanoplatforms also show a great potential in the diagnosis and treatment of AD.

conclusionsAlthough NIR-II theranostic agents showed the great potential in diagnosis and treatment of AD, there are still many challenges: 1) Faborable NIR-II fluorohpores are still lacking; 2) Biocompatibility, bioseurity and dosage of NIR-II theranostic agents should be further revealed; 3) New equipment and software associated with NIR-II imaging system should be explored.

Indexed as

Alzheimer DiseaseInfrared RaysTheranostic NanomedicineAnimalsHumansAlzheimer’s diseaseAmyloid-βNIR-II fluorescentTheranostic

Identifiers

PMID38502215

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.